The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex

  • PLoS Pathog. 2025 Jul 3;21(7):e1013258. doi: 10.1371/journal.ppat.1013258.
Pan-Pan Liu  1 Shu-Peng Jiang  2 Bang Li  1 Wen-Tao Gui  3 Xiang-Rong Qin  4 Xue-Jie Yu  1
Affiliations
  • 1. State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, China.
  • 2. Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
  • 3. Department of Genetics and Microbiology, Faculty of Science, Charles University, Prague, Czech Republic.
  • 4. Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Abstract

Inflammasomes function as immune-signaling platforms that were assembled following detection of pathogens. NLRP1 and CARD8 are related inflammasomes that use their C-terminal (CT) fragments containing a Caspase recruitment domain (CARD) and the UPA domain to initiate the inflammasome. At rest, dipeptidyl peptidases 8 and 9 (DPP8/9) inhibit inflammatory CT by interacting with the function-to-find domain (FIIND) of NLRP1/CARD8 and forming an inhibitory NLRP1/CARD8-DPP9 ternary complex consisting of DPP9, full-length NLRP1/CARD8, and NLRP1/CARD8 CT. However, the specific triggers of NLRP1 and CARD8 have not yet been fully identified. Here, we report that a tick-borne bunyavirus SFTSV Infection activates the NLRP1 inflammasome in primary keratinocytes and the CARD8 inflammasome in macrophages in a similar manner by targeting the ternary inhibitory complex, respectively. Mechanistically, SFTSV NSs interact with NLRP1 and CARD8 via their FIIND domains, suggesting that DPP8/9 are likely to compete for binding; on the Other hand, NSs promote the degradation of DPP8 and DPP9. Both contribute to more efficient destabilization of the DPP8/9 ternary complex and release the activated CT. Moreover, CARD8 deletion promotes SFTSV replication. In conclusion, we found a novel mechanism of viral protein activation of NLRP1 and CARD8 by disrupting the DPP9-binding checkpoint.

Products
Inhibitors & Agonists
Other Products